Cite les principaux faits historiques qui sont à l'origine de la mise en place et des premiers pas de l'aménagement forestier en Espagne pendant la deuxième moitié du XIXè siècle, ainsi que l'évolution au cours du XXè siècle et son état actuel. Si le bilan de ces 140 ans de pratique d'aménagement est globalement très positif, il reste cependant à combler d'importantes lacunes notamment en ce qui concerne les forêts issues de reboisements, ainsi qu'en ce qui concerne les méthodes de conversion fortement conditionnées par des facteurs sociaux et saisonniers surtout dans les forêts feuillues méditerranéennes souvent dégradées.
International audience ; Cite les principaux faits historiques qui sont à l'origine de la mise en place et des premiers pas de l'aménagement forestier en Espagne pendant la deuxième moitié du XIXè siècle, ainsi que l'évolution au cours du XXè siècle et son état actuel. Si le bilan de ces 140 ans de pratique d'aménagement est globalement très positif, il reste cependant à combler d'importantes lacunes notamment en ce qui concerne les forêts issues de reboisements, ainsi qu'en ce qui concerne les méthodes de conversion fortement conditionnées par des facteurs sociaux et saisonniers surtout dans les forêts feuillues méditerranéennes souvent dégradées.
Context. It appears that most (if not all) massive stars are born in multiple systems. At the same time, the most massive binaries are hard to find owing to their low numbers throughout the Galaxy and the implied large distances and extinctions. Aims. We want to study LS III +46 11, identified in this paper as a very massive binary; another nearby massive system, LS III +46 12; and the surrounding stellar cluster, Berkeley 90. Methods. Most of the data used in this paper are multi-epoch high S/N optical spectra, although we also use Lucky Imaging and archival photometry. The spectra are reduced with dedicated pipelines and processed with our own software, such as a spectroscopic-orbit code, CHORIZOS, and MGB. Results. LS III +46 11 is identified as a new very early O-type spectroscopic binary [O3.5 If∗ + O3.5 If∗] and LS III +46 12 as another early O-type system [O4.5 V((f))]. We measure a 97.2-day period for LS III +46 11 and derive minimum masses of 38.80 ± 0.83 M and 35.60 ± 0.77 M for its two stars. We measure the extinction to both stars, estimate the distance, search for optical companions, and study the surrounding cluster. In doing so, a variable extinction is found as well as discrepant results for the distance. We discuss possible explanations and suggest that LS III +46 12 may be a hidden binary system where the companion is currently undetected. ; J.M.A. and A.S. acknowledge support from [a] the Spanish Government Ministerio de Economia y Competitividad (MINECO) through grants AYA2010-15 081, AYA2010-17631, and AYA2013-40611-P and [b] the Consejeria de Educacion of the Junta de Andalucia through grant P08-TIC-4075. J.M.A. was also supported by the George P. and Cynthia Woods Mitchell Institute for Fundamental Physics and Astronomy and he is grateful to the Department of Physics and Astronomy at Texas A&M University for their hospitality during some of the time this work was carried out. I.N., A.M., J.A., and J.L. acknowledge support from [a] the Spanish Government Ministerio de Econoia y Competitividad (MINECO) through grant AYA2012-39364-C02-01/02, [b] the European Union, and [c] the Generalitat Valenciana through grant ACOMP/2014/129. R.H.B. acknowledges support from FONDECYT Project 1140076. S.S.-D. acknowledges funding by [a] the Spanish Government Ministerio de Economia y Competitividad (MINECO) through grants AYA2010-21697-C05-04, AYA2012-39 364-C02-01, and Severo Ochoa SEV-2011-0187 and [b] the Canary Islands Government under grant PID2 010 119. J.S.-B. acknowledges support by the JAE-PreDoc program of the Spanish Consejo Superior de Investigaciones Cientificas (CSIC). STScI is operated by the Association of Universities for Research in Astronomy, Inc., under NASA contract NAS5-26555. ; Peer Reviewed
According to recent market studies of the North American company Allied Market Research, the field of photonic sensors is an emerging strategic field for the following years and it is expected to garner $18 billion by 2021. The integration of micro and nanofabrication technologies in the field of sensors has allowed the development of new technological concepts such as lab-on-a-chip, which have achieved extraordinary advances in terms of detection and applicability, for example in the field of biosensors. This continuous development has allowed that equipment consisting of many complex devices that occupied a whole room a few years ago, at present it is possible to handle them in the palm of the hand; that formerly long duration processes are carried out in a matter of milliseconds and that a technology previously dedicated solely to military or scientific uses is available to the vast majority of consumers. The adequate combination of micro and nanostructured coatings with optical fiber sensors has permitted us to develop novel sensing technologies, such as the first experimental demonstration of lossy mode resonances (LMRs) for sensing applications, with more than one hundred citations and related publications in high rank journals and top conferences. In fact, fiber optic LMR-based devices have been proven as devices with one of the highest sensitivity for refractometric applications. Refractive index sensitivity is an indirect and simple indicator of how sensitive the device is to chemical and biological species, topic where this proposal is focused. Consequently, the utilization of these devices for chemical and biosensing applications is a clear opportunity that could open novel and interesting research lines and applications as well as simplify current analytical methodologies. As a result, on the basis of our previous experience with LMR based sensors to attain very high sensitivities, the objective of this paper is presenting the route for the development of label-free optical waveguide sensing platform ...
Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.
The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYS-ICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers).
The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYSICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers). ; Peer reviewed
Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.
Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.
Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified ARas mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIAWorld Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children. (J Allergy Clin Immunol 2012;130:1049-62.)